Thrombolytics in Acute Ischaemic Stroke: Historical Perspective and Future Opportunities

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cerebrovascular Diseases

• Publication date

  2013-04-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000348705PMID 23615379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data

  2015cited by this paper
• Stroke: advances in thrombolysis.

  2013cited by this paper
• t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes.

  2012cited by this paper
• Reducing in-hospital delay to 20 minutes in stroke thrombolysis

  2012cited by this paper
• Mechanical thrombolysis and stenting in acute ischemic stroke.

  2012cited by this paper
• A Multicentre, Randomized, Double-Blinded, Placebo-Controlled Phase III Study to Investigate Extending the Time for Thrombolysis in Emergency Neurological Deficits (EXTEND)

  2012cited by this paper
• Desmoteplase: discovery, insights and opportunities for ischaemic stroke

  2012cited by this paper
• A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.

  2012cited by this paper
• Vascular Occlusion Enables Selecting Acute Ischemic Stroke Patients for Treatment With Desmoteplase

  2012cited by this paper
• Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial.

  2012cited by this paper
• Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

  2012cited by this paper
• Current acute stroke trials and their potential impact on the therapeutic time window

  2012cited by this paper
• The Desmoteplase in Acute Ischemic Stroke (DIAS) Clinical Trial Program

  2012cited by this paper
• Plasminogen Activation and Thrombolysis for Ischemic Stroke

  2012cited by this paper
• Advances in translational medicine 2010.

  2011cited by this paper
• Reperfusion Therapies for Acute Ischemic Stroke: Current Pharmacological and Mechanical Approaches

  2011cited by this paper
• How to make better use of thrombolytic therapy in acute ischemic stroke

  2011cited by this paper
• Imaging in Acute Stroke

  2011cited by this paper
• Does it work?

  2011cited by this paper
• Tenecteplase for Acute Ischemic Stroke

  2011cited by this paper
• Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)

  2010cited by this paper
• Intravenous Alteplase for Stroke in Those Older Than 80 Years Old

  2010cited by this paper
• Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive

  2010cited by this paper
• Stroke: Working Toward a Prioritized World Agenda

  2010cited by this paper
• Thrombolysis at 3–4.5 Hours after Acute Ischemic Stroke Onset – Evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) Registry

  2010cited by this paper
• The “Golden Hour” and Acute Brain Ischemia: Presenting Features and Lytic Therapy in >30 000 Patients Arriving Within 60 Minutes of Stroke Onset

  2010cited by this paper
• ‘Where are we Now with Intravenous Thrombolysis for Acute Ischaemic Stroke’?

  2010cited by this paper
• Treating as Early as Possible with Thrombolysis Is Crucial, but Can We Do Better in the Sub-4.5-Hour Time Window?

  2010cited by this paper
• Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

  2010cited by this paper
• Comparison of Outcomes Following Thrombolytic Therapy Among Patients With Prior Stroke and Diabetes in the Virtual International Stroke Trials Archive (VISTA)

  2010cited by this paper
• Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR.

  2010cited by this paper
• Stroke: Working toward a Prioritized World Agenda

  2010cited by this paper
• Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

  2009cited by this paper
• Desmoteplase

  2009cited by this paper
• Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II).

  2009cited by this paper
• Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

  2009cited by this paper
• Acute ischemic stroke

  2009cited by this paper
• Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window

  2009cited by this paper
• Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

  2009cited by this paper
• Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.

  2008cited by this paper
• Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

  2008cited by this paper
• Stroke.

  2008cited by this paper
• Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

  2008cited by this paper
• A history of streptokinase use in acute myocardial infarction.

  2007cited by this paper
• Time Is Brain—Quantified

  2006cited by this paper
• Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study

  2006cited by this paper
• Imaging of acute stroke.

  2006cited by this paper
• Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset

  2006cited by this paper
• The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase

  2005cited by this paper
• Thrombolytic agents

  2005cited by this paper
• A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke

  2005cited by this paper
• Tissue‐type plasminogen activator: a historical perspective and personal account

  2004cited by this paper
• A History of Thrombolytic Therapy

  2004cited by this paper
• Diagnostic Accuracy of Stroke Referrals From Primary Care, Emergency Room Physicians, and Ambulance Staff Using the Face Arm Speech Test

  2003cited by this paper
• Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours

  2002cited by this paper
• A Review of Available Fibrin‐Specific Thrombolytic Agents Used in Acute Myocardial Infarction

  2001cited by this paper
• The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.

  2000cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial

  1999cited by this paper
• Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

  1999cited by this paper
• Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

  1999cited by this paper
• Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

  1998cited by this paper
• Thrombolytic therapy with streptokinase in acute ischemic stroke.

  1996cited by this paper
• New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.

  1995cited by this paper
• Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window.

  1995cited by this paper
• Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

  1995cited by this paper
• Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.

  1995cited by this paper
• RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE

  1995cited by this paper
• Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators (*)

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction

  1994cited by this paper
• The European Cooperative Acute Stroke Study (ECASS)

  1993cited by this paper
• Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset

  1992cited by this paper
• Thrombolysis in Acute Ischemic Stroke: Does It Work?

  1992cited by this paper
• Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes

  1992cited by this paper
• Thrombolytic agents.

  1991cited by this paper
• Strategies for the Improvement of Thrombolytic Agents

  1991cited by this paper
• The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression.

  1991cited by this paper
• Clinical Effects and Basic Studies of Thrombolytic Therapy on Cerebral Thrombosis

  1990cited by this paper
• Controlled Trial of Combined Urokinase and Dextran Sulfate Therapy in Patients With Acute Cerebral Infarction

  1986cited by this paper
• Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.

  1984cited by this paper
• Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.

  1984cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• A Pilot Study of Urokinase Therapy in Cerebral Infarction

  1976cited by this paper
• ANTICOAGULANTS PLUS STREPTOKINASE THERAPY IN PROGRESSIVE STROKE.

  1964cited by this paper
• Therapeutic thrombolysis in cerebral thromboembolism

  1963cited by this paper
• Thrombolysis With Fibrinolysin in Cerebral Arterial Occlusion

  1961cited by this paper
• Thrombolysis with fibrinolysin in cerebral arterial occlusion.

  1958cited by this paper
• The intravenous infusion of the streptococcal fibrinolytic principle (streptokinase) into patients.

  1955cited by this paper
• Staphylokinase: an Activator of Plasma Protease

  1948cited by this paper
• Fibrinolytic Activity of Normal Urine

  1947cited by this paper
• THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI

  1933cited by this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Safety and Efficacy of Alteplase in the Treatment of Acute Ischemic Stroke

  year unknowncited by this paper

• Unveiling melatonin's multifaceted actions against ferroptotic neurotoxicity in ischemic stroke.

  2026cites this paper
• Intravenous recombinant human prourokinase for acute ischemic stroke: a network meta-analysis.

  2025cites this paper
• Enhanced neurogenesis after ischemic stroke: The interplay between endogenous and exogenous stem cells

  2025influential citation
• Decoding ischemic stroke: Perspectives on the endoplasmic reticulum, mitochondria, and their crosstalk

  2025cites this paper
• An emerging role of SNAREs in ischemic stroke: From pre-to post-diseases.

  2025cites this paper
• Phosphodiesterase 4 inhibition as a novel treatment for stroke

  2025cites this paper
• Posterior circulation stroke case report: Labuan Bajo’s first intravenous thrombolysis

  2025influential citation
• Revolutionizing Ischemic Stroke Diagnosis and Treatment: The Promising Role of Neurovascular Unit-Derived Extracellular Vesicles

  2024cites this paper
• MiR-146a-5p downregulated TRAF6/NF-κB p65 pathway to attenuate the injury of HT-22 cells induced by oxygen–glucose deprivation/reoxygenation

  2024cites this paper
• Neuroprotection of Human Umbilical Cord-Derived Mesenchymal Stem Cells (hUC-MSCs) in Alleviating Ischemic Stroke-Induced Brain Injury by Regulating Inflammation and Oxidative Stress

  2024cites this paper
• To Compare the Efficacy and Safety of Teneplase and Alteplase in the Treatment of Acute Ischemic Stroke within 4.5 h

  2024cites this paper
• Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications

  2024cites this paper
• Sustained Release of Neuroprotective Drugs Curcumin and Edaravone from Supramolecular Hydrogel for Ischemic Stroke Treatment

  2023cites this paper
• Cell Membrane-Derived Nanovehicles for Targeted Therapy of Ischemic Stroke: From Construction to Application

  2023cites this paper
• Demethylnobiletin ameliorates cerebral ischemia‐reperfusion injury in rats through Nrf2/HO‐1 signaling pathway

  2023cites this paper
• Surface-tethered ROS-responsive micelle backpacks for boosting mesenchymal stem cell vitality and modulating inflammation in ischemic stroke treatment.

  2023cites this paper
• Fibrinolysis: an illustrated review

  2023cites this paper
• The combination of Ling Jiao Gou Teng decoction and ischemic preconditioning protect against cerebral ischemic reperfusion injury in rats by protecting the blood brain barrier

  2022cites this paper
• The AIM2 Inflammasome: A Novel Biomarker and Target in Cardiovascular Disease.

  2022cites this paper
• Diabetes and the treatment of ischemic stroke.

  2022cites this paper
• Recent Advances in Targeted Nanotherapies for Ischemic Stroke.

  2022cites this paper
• Research progress on the mechanism of action of hesperetin in cerebral ischemia: a narrative review

  2022cites this paper
• Treatments in Neurology: The Winding Road from 1897 to 2022

  2022cites this paper
• Dexmedetomidine Inhibits NF-κB-Transcriptional Activity in Neurons Undergoing Ischemia-Reperfusion by Regulating O-GlcNAcylation of SNW1.

  2022cites this paper
• Structure-Activity Relationship Studies of Functionalized Aromatic Peptidomimetics as Neurolysin Activators.

  2022cites this paper
• Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke

  2022cites this paper
• Adapting Clinical Practice of Thrombolysis for Acute Ischemic Stroke Beyond 4.5 Hours: A Review of the Literature.

  2021cites this paper
• Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window

  2021cites this paper
• Recent advances in the development of nanomedicines for the treatment of ischemic stroke

  2021cites this paper
• A novel brain targeted plasma exosomes enhance the neuroprotective efficacy of edaravone in ischemic stroke

  2021cites this paper
• A new thrombolytic drug for acute ischaemic stroke.

  2021cites this paper
• Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein.

  2021cites this paper
• Artificial Intelligence in Acute Ischemic Stroke

  2021cites this paper
• Stroke

  2021cites this paper
• Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)

  2021cites this paper
• Preclinical modeling of mechanical thrombectomy.

  2021cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase

  2021cites this paper
• FACTORS CAUSING DELAY IN TIME TO DOOR AT EMERGENCY DEPARTMENT(ED) IN CASES OF ACUTE STROKE AND IT'S IMPACT ON OUTCOME AT TERTIARY CARE CENTRE

  2020cites this paper
• Curcumin exerts protective effects against hypoxia-reoxygenation injury via the enhancement of apurinic/apyrimidinic endonuclease 1 in SH-SY5Y cells: Involvement of the PI3K/AKT pathway

  2020influential citation
• Recent Progress in Autocatalytic Ceria Nanoparticles-Based Translational Research on Brain Diseases

  2020cites this paper
• Fibrinolytic Capacity of Desmoteplase Compared to Tissue Plasminogen Activator in Rabbit Eyes

  2019cites this paper
• Outcome of Thrombolysis with Alteplase in Acute Ischemic Stroke

  2019cites this paper
• Predicting the Response to Non-invasive Brain Stimulation in Stroke

  2019cites this paper
• Point mutation in amino acid 263 of streptokinase gene as well as cloning and expression of the cysteine containing mutated protein

  2019cites this paper
• Passivating Injured Endothelium with Kinexins in Thrombolytic Therapy

  2018cites this paper
• Free Radical Damage in Ischemia-Reperfusion Injury: An Obstacle in Acute Ischemic Stroke after Revascularization Therapy

  2018cites this paper
• Stroke: The past, present and future

  2018cites this paper
• Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy.

  2018cites this paper
• Dosage Calculation for Intravenous Thrombolysis of Ischemic Stroke: To Weigh or to Estimate

  2017cites this paper
• Thrombolytic Therapy Targeting Alpha 2-Antiplasmin

  2017cites this paper
• Thrombolysis and thrombectomy for acute ischaemic stroke

  2017cites this paper
• Castanea sativa Mill. Bark Extract Protects U‐373 MG Cells and Rat Brain Slices Against Ischemia and Reperfusion Injury

  2017influential citation
• Treatment of Acute Ischemic Stroke.

  2016cites this paper
• Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis

  2016cites this paper
• Tissue Plasminogen Activator: A Literature Review

  2016cites this paper
• Angiographic and Clinical Factors Related with Good Functional Outcome after Mechanical Thrombectomy in Acute Cerebral Artery Occlusion

  2015cites this paper
• Endovascular Treatment versus Sonothrombolysis for Acute Ischemic Stroke

  2015cites this paper
• Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions.

  2015cites this paper
• Recombinant tissue plasminogen activators (rtPA): A review

  2015cites this paper
• Nanotheragnostic Applications for Ischemic and Hemorrhagic Strokes: Improved Delivery for a Better Prognosis

  2014cites this paper
• Effects of a TAFI-Inhibitor Combined with a Suboptimal Dose of rtPA in a Murine Thromboembolic Model of Stroke

  2014cites this paper
• ISOLATION, CLONING AND EXPRESSION OF RECOMBINANT STAPHYLOKINASE GENE AGAINST THROMBOSIS

  2014cites this paper
• Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit–risk analysis of clinical trials

  2014cites this paper
• Front & Back Matter

  2014cites this paper
• Reperfusion Therapies of Acute Ischemic Stroke: Potentials and Failures

  2014cites this paper